Clinical performance of the Roche Elecsys SARS-CoV-2 antigen fully automated electrochemiluminescence immunoassay
Objective: We assessed the clinical performance of novel Roche Elecsys SARS-CoV-2 Antigen fully automated electrochemiluminescence immunoassay (ECLIA). Design and methods: We tested 160 subjects, 110 (68.8%), with positive molecular test for SARS-CoV-2 infection in nasopharyngeal samples, with Alton...
Main Authors: | Gian Luca Salvagno, Laura Pighi, Simone De Nitto, Giuseppe Lippi |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-03-01
|
Series: | Practical Laboratory Medicine |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S235255172200004X |
Similar Items
-
Association between viral load and positivization time of a SARS-CoV-2 rapid antigen test in routine nasopharyngeal specimens
by: Salvagno Gian Luca, et al.
Published: (2022-01-01) -
Real-world assessment of Fluorecare SARS-CoV-2 Spike Protein Test Kit
by: Salvagno Gian Luca, et al.
Published: (2021-05-01) -
The Androstenedione Roche Elecsys immunoassay has superior comparability to the LC-MS/MS assay than the Siemens Immulite immunoassay
by: Ruhan Wei, et al.
Published: (2022-08-01) -
Comparison of chemiluminescent microparticle immunoassay (CMIA) with electrochemiluminescence immunoassay (ECLIA) for Carcinoembryonic antigen (CEA)
by: Nafija Serdarevic, et al.
Published: (2018-09-01) -
Evaluation of Fully Automated Electrochemiluminescence Immunoassay for Rapid Detection of Hepatitis B surface antigen and antibodies to Hepatitis C Virus
by: Ola Wasfi, et al.
Published: (2009-03-01)